A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer-Reference-Cited by-同舟云学术

A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer

Published:2022-08-20 Issue:1 Volume:11 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Avanzino Brian C.¹²,Prabhakar Kirthana¹²,Dalvi Pranjali¹²^ORCID,Hartstein Sharon¹³,Kehm Hannes¹,Balasubramani Aarti¹³,Boudreau Andrew A.¹^ORCID,Buelow Ben¹,Chang Karen¹,Davison Laura M.¹,Iyer Suhasini¹,Kalwit Vidyut¹²,Lewis Wilson Kristin⁴,Malik-Chaudhry Harbani K.¹³^ORCID,Pierson Will⁵⁶,Pineda Geovanni⁵⁷,Rangaswamy Udaya S.¹²^ORCID,Saiganesh Sowmya¹²,Schellenberger Ute¹^ORCID,Ugamraj Harshad S.¹⁸,Yabut Rodolfovan D.⁴,Buelow Roland¹,Chapman Jocelyn⁵⁷,Trinklein Nathan D.¹,Harris Katherine E.¹²^ORCID

Affiliation:

1. Teneobio, Inc, Newark, CA, United States

2. Oncology Research, Amgen Inc., Newark, CA, USA

3. Therapeutic Discovery, Amgen Inc., Newark, CA, USA

4. Translational Safety & Bioanalytical Sciences, Amgen Inc., South San Francisco, CA, USA

5. Division of Gynecologic Oncology, University of California, San Francisco, CA, USA

6. University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

7. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA

8. Process Development, Amgen Inc., Newark, CA, USA

Funder

Teneobio and in part by NIH SBIR

Publisher